glatiramer acetate / Generic mfg.  >>  Phase 4
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glatiramer acetate / Generic mfg.
2004-004903-39: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.

Ongoing
4
60
Europe
Mitoxantrone, Glatiramer Acetate, Interferon Beta 1a, , Injection*, Mitoxantrone, Copaxone, Rebif 44
The Walton Centre for Neurology and Neurosurgery
Early, active relapsing remitting Multiple Sclerosis (RRMS)
 
 
2014-001012-19: Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosis De effecten van fingolimod op geavanceerde hersenmaten en klinische maten in multiple sclerose

Ongoing
4
70
Europe
Interferon Beta, Capsule, , Solution for injection in pre-filled syringe, Gilenya, Copaxone
VU University Medical Center, Novartis Pharma
Relapsing-remitting (RR) multiple sclerosis (MS) Relapsing-remitting (RR) multiple sclerose (MS), multiple sclerosis (MS) multiple sclerose (MS), Diseases [C] - Nervous System Diseases [C10]
 
 
2009-013129-41: A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneously or after no treatment, in patients with a clinical isolated syndrome, other than optic neuritis or early relapsing remitting multiple sclerosis patients

Ongoing
4
30
Europe
Copaxone, Copaxone, Copaxone
Amphia Ziekenhuis
clinical isolated syndrome
 
 
2009-011088-35: Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial

Ongoing
4
30
Europe
copaxone, 52069.00.01, Copaxone, Copaxone
Philipps-Universität Marburg
Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive intestinal polypaptide/pituitary adenylate cyclase activating polypeptide) system in stresses patients who start a immunomodulatory treatment with glatiramer acetate (Copaxone).
 
 
2011-000150-31: EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. Effetti della terapia con Glatiramer Acetato (Copaxone)sul danno tissutale, sulle funzioni corticali e sulla fatica nella Sclerosi Multipla: studio morfofunzionale con risonanza magnetica.

Ongoing
4
30
Europe
COPAXONE, COPAXONE
FONDAZIONE DON CARLO GNOCCHI ONLUS
Multiple Sclerosis patients Soggetti affetti da Sclerosi Multipla
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2016-004819-12: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients Sclerosi Multipla: effetti della sospensione del trattamento protratto con farmaci immunomodulanti di prima linea in pazienti "full responders"

Ongoing
4
300
Europe
Interferone Beta-1B, Inteferone Beta-1A, Glatiramer acetato, Interferon Beta-1a, [032166011], [033283045], [035418060], [034091165], Powder and solvent for solution for injection, Solution for injection, BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML, AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE, COPAXONE - "40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA" 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO, REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE
OSPEDALE SAN RAFFAELE, AIFA - Italian Medicines Agency
Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04878211: A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Terminated
4
24
US
Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis (RMS)
04/23
04/23
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30

Download Options